Sector: Biotechnology - Drug Delivery
Medical Field: General Health
Technological Field: Oral Drug Delivery
Year Established: 2002
Chiasma creates proprietary oral drug products that aim to lengthen the life cycle of compounds (increase market size and share) by addressing significant unmet clinical needs of injectable macro- and small molecules through the use of its Transient Permeability Enhancer (TPE) platform.
Chiasma’s proprietary Transient Permeability Enhancer (TPE) platform enables oral delivery of macromolecules and poorly absorbed small molecules into the bloodstream with therapeutically relevant bioavailability. The TPE technology is versatile, can be applied to a wide range of therapeutic agents, requires no chemical modification of the drug and is cost effective.